Effective treatment of major depressive disorder with antidepressants is currently limited by factors that affect treatment compliance, including delay in onset of therapeutic effects and, often, intolerable side-effects. Recent data suggest that use of antidepressant combinations with different mechanisms of action may be a better first-line strategy prior to augmentation with other drug classes. The rationale for this approach is that combining multiple pharmacological actions affecting multiple monoamine targets produces greater efficacy. The latest data on multimodal therapies indicate shorter onset of therapeutic effects and improved tolerability. By modulating multiple receptors and neurotransmitter systems, it is hoped that these new agents may also treat some of the associated symptoms of major depressive disorder, such as anxiety and cognitive dysfunction.
Improve your knowledge in the field of psychiatry by taking Elsevier's complimentary pain medicine continuing medical education courses.
An Update on Scientific Advances and Clinical Strategies in Alzheimer’s Disease: Conference Reporter from AD/PD™ 2017Format: Conference Reporter
The Alzheimer’s & Parkinson’s Diseases (AD/PD™) 13th International Conference was held in Vienna, Austria, March 29 to April 2, 2017. The conference attracts international medical and scientific professionals worldwide and is at the forefront of unraveling the mechanisms and improving the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD). In this activity, 2 experts summarize the key learnings from this year’s conference focusing on AD.
Alzheimer’s Disease in Primary Care: The Significance of Early Detection, Diagnosis, and InterventionFormat: Webcast
The field of Alzheimer’s disease (AD) is undergoing a profound and rapid change: clinical trials have been redesigned to focus on individuals in the earliest stages of the disease and are including more sensitive measurement tools to better capture changes in cognition and other outcomes. Trial participants undergo PET imaging for amyloid load as a hallmark for dementia, as well as genetic testing to determine likelihood of disease progression and response to therapeutic intervention. Large national and international registries have been established to capture those at risk and to follow their development of cognitive changes longitudinally. Understanding that the disease process starts at least a decade or more before the onset of symptoms has prompted the development of therapeutic interventions acting very early in the disease cascade. For all these reasons, recognizing and diagnosing AD early offers affected individuals and their caregivers the best chance for care planning, access to available symptomatic treatment and community resources, as well as involvement with clinical trials and access to new therapies when they become available. Primary care clinicians play a pivotal role in the early recognition of cognitive impairment in their patients.